GlassScriptPhysician profile
Ryan C Francis
NPI 1306367834
$3,462.68
in general payments reported to CMS, 2019-2025
32 companies · $1,141 in 2025
The $1,141 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $405 · 2022: $343 · 2023: $600 · 2024: $973 · 2025: $1,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,654 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,653.55 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $913.84 | 2021-2025 | |
| Indivior INC. | $288.47 | 2022-2025 | Sublocade |
| Ardelyx, INC. | $221.18 | 2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $213.46 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $169.78 | 2021-2025 | Jardiance, Mounjaro |
| Axsome Therapeutics, INC. | $158.72 | 2025 | Auvelity, Sunosi |
| Welch Allyn | $131.21 | 2021 | |
| Verona Pharma, INC. | $121.69 | 2025 | Ohtuvayre |
| Amgen INC. | $108.83 | 2024 | Otezla, Repatha |
| Silk Road Medical, INC. | $106.17 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.66 | 2023-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $101.69 | 2024 | Spravato |
| Astellas Pharma US INC | $94.06 | 2023-2024 | Veozah |
| Teleflex LLC | $94.02 | 2023 | Urolift |
| Gilead Sciences, INC. | $89.92 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $74.43 | 2023 | Titan |
| Exact Sciences Corporation | $64.86 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Braeburn INC. | $63.33 | 2024-2025 | Brixadi |
| Dexcom, INC. | $53.95 | 2024-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $39.33 | 2023-2024 | |
| Glaxosmithkline, LLC. | $34.01 | 2023-2025 | Trelegy Ellipta |
| Alkermes, INC. | $29.60 | 2025 | Vivitrol |
| Abbott Laboratories | $26.62 | 2025 | Freestyle Libre 3 |
| Ani Pharmaceuticals, INC. | $22.93 | 2025 | Purified Cortrophin Gel |
| Global Blood Therapeutics, INC. | $18.59 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.22 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $17.74 | 2025 | |
| Insulet Corporation | $17.29 | 2024 | Omnipod |
| Ironshore Pharmaceuticals INC. | $17.24 | 2024 | |
| Noven Therapeutics, LLC | $17.21 | 2025 | Xelstrym |
| Averitas Pharma INC. | $16.69 | 2024 | Qutenza |
| Novo Nordisk INC | $14.94 | 2024 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Francis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.